Bryan Johnson· Author
The FDA recently approved the Lumipulse G test, which utilizes pTAU217/A𝛃42, as the first blood test for early detection of Alzheimer's disease in symptomatic individuals over 55.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
The FDA recently approved the Lumipulse G test, which utilizes pTAU217/A𝛃42, as the first blood test for early detection of Alzheimer's disease in symptomatic individuals over 55.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
The FDA just approved approved pTAU217/A𝛃42 ratio as the first blood test for the early detection of Alzheimer disease.
The FDA just approved a blood test that can spot signs of Alzheimer's before the symptoms emerge. It's called Lumipulse G and it identifies a protein in your blood called PTA 217.